Lancet Diabetes & Endocrinology

Papers
(The H4-Index of Lancet Diabetes & Endocrinology is 71. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Direct-to-consumer services: improving access to care for people with diabetes and obesity1088
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale954
South Africa to produce insulin for Africa in 2024867
Reassessing driving safety in diabetes634
Better testing and labelling of drugs for people with obesity588
Anand Hardikar: a scientific nomad searching for the truth579
What's preventing us from curbing the obesity crisis?489
A framework for improving diabetes care in humanitarian emergencies422
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial279
Artificial intelligence and diabetes: time for action and caution243
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-2242
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98232
International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity231
Specific cortisol blockade in Cushing's syndrome219
Implications of technology guidelines for low-income and middle-income countries219
Clinical features, investigation, and management of Addison's disease201
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?196
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial191
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality190
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p186
Artificial intelligence for interpreting diabetes data using clinician-curated benchmarks179
Comparison of incidence patterns and risk profiles of ST-elevation and non-ST-elevation myocardial infarction in type 1 diabetes in Finland: a nationwide cohort study175
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions171
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice165
Type 1 diabetes screening: need for ethical, equity, and health systems perspective165
World Health Assembly ratifies first global diabetes targets164
Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial160
What does renal failure teach us about our National Health System?130
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study130
Challenging diabetes stigma starts and ends with all of us127
Glycaemic index as part of the diabetes prevention strategy126
The role of nurses in diabetes care: challenges and opportunities119
Cardiovascular mortality trends among people with and without diabetes115
A roadmap for integrating mental health and diabetes services113
Levothyroxine treatment in euthyroid women positive for thyroid peroxidase antibodies and recurrent pregnancy loss113
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials112
3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial110
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin107
Healthy weight for the next generation's health in China105
The urgent need for a diabetes data rights charter101
Rising diabetes diagnosis in long COVID100
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing99
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply99
Putting wellbeing at the core of diabetes care99
Explaining the high rate of progression from prediabetes to type 2 diabetes in China98
Correction to Lancet Diabetes Endocrinol 2025; published online April 7. https://doi.org/10.1016/S2213-8587(25)00087-797
Correction to Lancet Diabetes Endocrinol 2025; published online Nov 19. https://doi.org/10.1016/S2213-8587(25)00289-X97
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses95
Trajectories of type 2 diabetes and cancer in 330 000 individuals with prediabetes: 20-year observational study in England93
Diabetes and mental health92
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history91
Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial90
The promise and hope of GLP-1 receptor agonists89
The uncomfortable truth about kidney disease in type 1 diabetes89
Correction to Lancet Diabetes Endocrinol 2025; 13: 935–4885
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study85
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis84
Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement81
Understanding the mechanism of prediabetes remission in young people80
CONCEPTT to care: the science of implementation in diabetes care80
Diabetes: knowing your risk matters77
Gender equality: timely and timeless77
Balancing hormonal shifts: exploring the impact of ageing and dietary restriction76
Improving HbA1c levels with advanced hybrid closed-loop therapy75
Is it time to re-assess the development of thyroid function reference ranges?75
A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international75
The long and winding road to precision diabetology74
Bothersome vasomotor symptoms: a potential early clinical marker of perimenopause?74
Correction to Lancet Diabetes Endocrinol 2022; 10: 407–1773
Blood pressure control according to type 2 diabetes status72
Correction to Lancet Diabetes Endocrinol 2022; 10: 481–8371
0.10760402679443